Hi Connie, sorry it may be a silly question but has he been exposed to oxaliplatin (eg via FOLFOX) before? This is a common first-line, along with FOLFIRI. Depending on some other factors an anti-VEGF drug such as Avastin (bevacizumab) may also often be considered.
Given he has been on Erbitux I presume he doesn’t have a RAS mutation... do you happen to know his MSS status and/or tumour mutation burden (TMB)? This would be important for potential immunotherapy routes (eg Keytruda/Opdivo).
The folk at CoH should be all over this stuff though anyway. Best wishes to you both.
10/2018 Dx 3.5cm RC adenocarcinoma, 12cm high
Mod diff, EMVI+ LVI+. 4 liver mets
pT3N1aM1a Stage IVa. MSS NRAS G13R
CEA: Oct-18= 12; Nov-18= 14, Mar-19= 2.4, Aug-19 <2.0, Mar-20=2.2, May-20=1.9, Jun-20=2.1
11/18 FOLFOX x6
3/19 Liver resect
5/19 25x pelvic VMAT radiation; complete met. response
07/19 Robot ULAR w ileo, 1/27 LN+
08/19 Found liver spot
08/19 FOLFOX x1, FOLFOXIRI x1, FOLFIRI x5
12/19 Liver resect #2
02/20 Ileo reversed
03/20 NED (PET+MRI)
06/20 NED (CT+MRI)
07/20 Clear scope